Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The OptiPlate™ is one of the most versatile microplates offered by PerkinElmer, used in many different applications, assays, and instruments. The optimized well design and high quality plastics provides low background and crosstalk.
OptiPlates are uniquely engineered to be the same height for 96-, 384-, and 1536-well plates, and with extraordinary well flatness for ease in automation.
Leveraging years of assay and instrument experience in plate detection, PerkinElmer designs better microplates for better performance that guarantees better results for all PerkinElmer applications.
Well format: 384-well
|Number of Rows||16|
|Number of Columns||24|
|Well volume||105 µL|
|Recommended working volume||24 µL – 90 µL|
|Well diameter (mm)||3.65|
|Well depth (mm)||10.4|
|A1 to top offset (mm)||9|
|A1 to side offset (mm)||12.1|
|Well-to-well spacing (mm)||4.5|
|Detection Method||Luminescence, Alpha, Time-Resolved Fluorescence (TRF & TR-FRET), Radiometric|
|Product Brand Name||OptiPlate|
|Unit Size||Case of 50|
|Wells Number||384 well plate|
Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.
Immune checkpoints serve a critical role in the immune system to prevent autoimmunity and manage the degree and duration of an immune response. Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4 or CD152) is an inhibitory transmembrane protein involved in an immune checkpoint of significant interest for therapeutic development. When CTLA-4 is expressed and competes with CD28, the immune system response is downregulated. As a result of this immune system response balance, immune checkpoints provide an opportunity for therapeutic intervention to modulate immune system activity.
There is a high demand for new drugs to block CTLA-4 and modulate immune system activity. In this application note, we demonstrate how to screen for novel CTLA-4 blocking drugs by utilizing the AlphaLISA CTLA-4/CD80 binding assay.